[S01GX11, alcaftadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alcaftadine.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Trazodone is combined with Streptokinase.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trazodone.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Trazodone is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Trazodone.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Azapropazone.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Trazodone.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.]
[G03BA03, testosterone, The metabolism of Trazodone can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Trazodone.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Apomorphine.]
[L04AX02, thalidomide, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Trazodone.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.]
[N05AB08, thioproperazine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Trazodone.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Trazodone is combined with Moxisylyte.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Trazodone.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Trazodone.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Trazodone.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Trazodone is combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Timolol.]
[M02AX02, tolazoline, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Trazodone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Trazodone.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trazodone is combined with Trapidil.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Trazodone.]
[S01BA05, triamcinolone, The metabolism of Trazodone can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Trazodone.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Trazodone.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.]
[N04AA01, trihexyphenidyl, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Trazodone can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Trimethadione.]
[C02BA01, trimethaphan, Trazodone may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Trimipramine.]
[R06AC04, tripelennamine, The metabolism of Trazodone can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Triprolidine.]
[A03BB01, butylscopolamine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The serum concentration of Trazodone can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tryptophan.]
[C09CA09, azilsartan medoxomil, Trazodone may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Trazodone.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Trazodone can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.]
[J05AP03, boceprevir, The serum concentration of Trazodone can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Trazodone can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Trazodone is combined with Urokinase.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Trazodone is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Trazodone is combined with Ticagrelor.]
[C08DA01, verapamil, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.]
[N06AX09, viloxazine, The metabolism of Trazodone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be decreased when it is combined with Trazodone.]
[C04AX07, vincamine, Trazodone may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The serum concentration of Vincristine can be decreased when it is combined with Trazodone.]
[B01AA03, warfarin, Trazodone may decrease the anticoagulant activities of Warfarin.]
[S01AA13, fusidic acid, The metabolism of Trazodone can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Trazodone is combined with Xenon.]
[C03BA10, xipamide, Trazodone may decrease the antihypertensive activities of Xipamide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Trazodone can be increased when it is combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Trazodone.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tolterodine.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Trazodone.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Trazodone.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Atropine.]
[L01EK01, axitinib, The serum concentration of Axitinib can be decreased when it is combined with Trazodone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Trazodone.]
[H02AB11, prednylidene, The metabolism of Trazodone can be increased when combined with Prednylidene.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be decreased when it is combined with Trazodone.]
[G04BE10, avanafil, Trazodone may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[A08AA11, lorcaserin, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be decreased when it is combined with Trazodone.]
[V03AX03, cobicistat, The serum concentration of Trazodone can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Trazodone can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be decreased when it is combined with Trazodone.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Trazodone is combined with Defibrotide.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Trazodone.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be decreased when it is combined with Trazodone.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Trazodone.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be decreased when it is combined with Trazodone.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Trazodone.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Trazodone is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Trazodone.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Trazodone can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Trazodone.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Trazodone.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Trazodone.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Trazodone is combined with Apixaban.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Trazodone.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Trazodone can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.]
[G03XC05, ospemifene, The metabolism of Trazodone can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Trazodone.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Moxifloxacin.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Trazodone.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Trazodone.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Trazodone.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Naratriptan.]
[L04AA18, everolimus, The serum concentration of Everolimus can be decreased when it is combined with Trazodone.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trazodone.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Trazodone.]
[L01EB03, afatinib, The serum concentration of Afatinib can be decreased when it is combined with Trazodone.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bepridil.]
[C02KX05, riociguat, Trazodone may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Trazodone may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Trazodone.]
[N06AX26, vortioxetine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Trazodone.]
[J05AP05, simeprevir, The metabolism of Trazodone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be decreased when it is combined with Trazodone.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Trazodone.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Trazodone.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Trazodone.]
[C07AB04, acebutolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Trazodone.]
[A16AA07, metreleptin, The metabolism of Trazodone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Trazodone can be increased when combined with Apremilast.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Trazodone.]
[S03BA03, betamethasone, The metabolism of Trazodone can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Trazodone is combined with Argatroban.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Trazodone.]
[L04AC11, siltuximab, The metabolism of Trazodone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Trazodone is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hyoscyamine.]
[B01AA07, acenocoumarol, Trazodone may decrease the anticoagulant activities of Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Trazodone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Olodaterol.]
[D11AA01, glycopyrronium, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Trazodone can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Trazodone.]
[N04AA02, biperiden, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Trazodone.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Trazodone.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Trazodone.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Trazodone is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Trazodone is combined with Edoxaban.]
[N06AX11, mirtazapine, Trazodone may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Trazodone can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Trazodone.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Trazodone.]
[A03AA09, difemerine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Trazodone is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Trazodone can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Trazodone is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Trazodone can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Trazodone.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Trazodone.]
[A02BC03, lansoprazole, The metabolism of Trazodone can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Trazodone.]
[J02AC05, isavuconazole, The metabolism of Trazodone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be decreased when it is combined with Trazodone.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Trazodone.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be decreased when it is combined with Trazodone.]
[B01AC27, selexipag, Trazodone may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alfuzosin.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Trazodone.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Trazodone.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Trazodone.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be decreased when it is combined with Trazodone.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone.]
[N04BC01, bromocriptine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Trazodone.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Trazodone.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bupranolol.]
[N07BC01, buprenorphine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Azatadine.]
[S01GX07, azelastine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Trazodone can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Trazodone.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Trazodone.]
[C09AA07, benazepril, Trazodone may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trazodone.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Trazodone.]
[J05AE09, tipranavir, The serum concentration of Trazodone can be increased when it is combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Trazodone.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Trazodone.]
[L04AB02, infliximab, The metabolism of Trazodone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of Trazodone can be increased when it is combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Trazodone.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Trazodone.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Trazodone is combined with Betrixaban.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Trazodone.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Trazodone.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be decreased when it is combined with Trazodone.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be decreased when it is combined with Trazodone.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Trazodone.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Trazodone.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Efavirenz.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Trazodone.]
[N04AA11, bornaprine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Trazodone.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Trazodone.]
[R03BA02, budesonide, The metabolism of Trazodone can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Trazodone is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Trazodone can be decreased when combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Trazodone.]
[J05AX18, letermovir, The metabolism of Trazodone can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Acetyldigoxin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Trazodone.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Acrivastine.]
[C09AA01, captopril, Trazodone may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Trazodone can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Trazodone can be decreased when it is combined with Carbamazepine.]
[A03AA03, camylofine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Trazodone.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Carbinoxamine.]
[C07AG02, carvedilol, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Trazodone.]
[N03AX24, cannabidiol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cannabidiol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be decreased when it is combined with Trazodone.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Trazodone.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Trazodone.]
[N03AX17, stiripentol, The serum concentration of Trazodone can be increased when it is combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Trazodone.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be decreased when it is combined with Trazodone.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Trazodone.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trazodone.]
[R06AA06, chlorphenoxamine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be decreased when it is combined with Trazodone.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone.]
[R03BB08, revefenacin, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Trazodone.]
[L04AA39, emapalumab, The metabolism of Trazodone can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Trazodone can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cibenzoline.]
[C09AA08, cilazapril, Trazodone may decrease the antihypertensive activities of Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Trazodone is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cinitapride.]
[S01ED05, carteolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Trazodone.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Trazodone is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Trazodone.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Trazodone.]
[N05BA09, clobazam, The metabolism of Trazodone can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Trazodone can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Trazodone.]
[C09CA06, candesartan, Trazodone may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Trazodone can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Trazodone can be increased when combined with Cortivazol.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Trazodone.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Trazodone can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Entrectinib.]
[N07XX11, pitolisant, The therapeutic efficacy of Pitolisant can be decreased when used in combination with Trazodone.]
[J01XX12, lefamulin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Trazodone.]
[C03AA09, cyclothiazide, Trazodone may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Yohimbine.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trazodone.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Trazodone can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Trazodone can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Trazodone.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Trazodone.]
[M01AX21, diacetylrhein, The metabolism of Trazodone can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Trazodone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Trazodone can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Trazodone is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Trazodone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Trazodone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Trazodone.]
[N02AA08, dihydrocodeine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Trazodone is combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Trazodone.]
[S03AA08, chloramphenicol, The metabolism of Trazodone can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.]
[C02AA06, methoserpidine, Trazodone may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Trazodone.]
[A03AA08, dihexyverine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Trazodone.]
[D07XB03, fluprednidene, The metabolism of Trazodone can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Trazodone.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Trazodone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Trazodone is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Trazodone can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Trazodone is combined with Remimazolam.]
[N07XX04, sodium oxybate, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Trazodone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Trazodone is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Trazodone can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of hyponatremia can be increased when Trazodone is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trazodone.]
[A11CC05, cholecalciferol, The metabolism of Trazodone can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Trazodone.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Trazodone.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trazodone.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be decreased when it is combined with Trazodone.]
[A16AX20, lonafarnib, The serum concentration of Trazodone can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be decreased when it is combined with Trazodone.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Trazodone is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Trazodone can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Trazodone.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Fenbufen.]
[C01CA19, fenoldopam, Trazodone may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Trazodone is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Trazodone is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Trazodone.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Trazodone.]
[L03AB10, peginterferon alfa-2b, The metabolism of Trazodone can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Trazodone may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.]
[A02BA01, cimetidine, The metabolism of Trazodone can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Trazodone can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Trazodone is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Trazodone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Mefenamic acid.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Trazodone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Trazodone.]
[N06AX25, St. John's wort extract, The serum concentration of Trazodone can be decreased when it is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Trazodone.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Trazodone is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trazodone.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Trazodone.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Trazodone.]
[C01EB24, mavacamten, The serum concentration of Trazodone can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Trazodone.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Trazodone.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Trazodone.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Granisetron.]
[J05AX31, lenacapavir, The serum concentration of Lenacapavir can be decreased when it is combined with Trazodone.]
[L01XX77, adagrasib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Adagrasib.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be decreased when it is combined with Trazodone.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Trazodone.]
[H01AC08, somatrogon, The metabolism of Trazodone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Trazodone.]
[L04AC21, bimekizumab, The metabolism of Trazodone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Trazodone.]
[A03AB10, hexocyclium, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Trazodone.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Trazodone.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Trazodone.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Trazodone.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Trazodone is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Valdecoxib.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Trazodone.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Trazodone is combined with Bemiparin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Trazodone.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levocabastine.]
[S01BA03, cortisone, The metabolism of Trazodone can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Trazodone.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Loxoprofen.]
[C09AA03, lisinopril, Trazodone may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Trazodone can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Trazodone.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Trazodone is combined with Mefenorex.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Trazodone.]
[H02AB15, meprednisone, The metabolism of Trazodone can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Adenosine.]
[N04AA03, methixene, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Trazodone is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Trazodone.]
[C03DA04, eplerenone, Trazodone may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Trazodone.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Trazodone.]
[S01XA18, cyclosporine, The metabolism of Trazodone can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Trazodone.]
[N06BA07, modafinil, The metabolism of Trazodone can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Trazodone.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Morniflumate.]
[C03XA02, conivaptan, The serum concentration of Trazodone can be increased when it is combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Trazodone.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Vardenafil.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Etoricoxib.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be decreased when it is combined with Trazodone.]
[G03XA01, danazol, The serum concentration of Trazodone can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.]
[J04BA02, dapsone, The metabolism of Trazodone can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Trazodone can be increased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Trazodone.]
[C02CC04, debrisoquin, Trazodone may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Trazodone.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Trazodone.]
[N06AX06, nefazodone, The serum concentration of Trazodone can be increased when it is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Trazodone.]
[C01DX16, nicorandil, Trazodone may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Trazodone.]
[C01CA23, theodrenaline, Trazodone may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trazodone.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Trazodone.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Normethadone.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Trazodone is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Trazodone is combined with Desmopressin.]
[C09XA02, aliskiren, Trazodone may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Trazodone.]
[S03BA01, dexamethasone, The serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Trazodone.]
[N04AA08, dexetimide, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Trazodone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Trazodone can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Trazodone.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dextromoramide.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Trazodone.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Trazodone is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Trazodone.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Trazodone.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Trazodone.]
[V03AH01, diazoxide, Trazodone may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Trazodone.]
[N06AA08, dibenzepin, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Foscarnet.]
[A03AA07, dicyclomine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Trazodone may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pipamperone.]
[A03AB14, pipenzolate, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Erlotinib.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Trazodone.]
[A08AA03, diethylpropion, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Trazodone can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Digitoxin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Trazodone.]
[C02DB01, dihydralazine, Trazodone may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Trazodone is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Hydromorphone.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Treprostinil.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Trazodone.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Trazodone.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Trazodone.]
[R06AB03, dimethindene, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Trazodone.]
[M02AX03, dimethyl sulfoxide, The metabolism of Trazodone can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Trazodone.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Trazodone.]
[C09AA06, quinapril, Trazodone may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Trazodone is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Trazodone is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Cisapride.]
[C09AA05, ramipril, Trazodone may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be decreased when it is combined with Trazodone.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Trazodone.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Trazodone can be decreased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Trazodone can be decreased when it is combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Trazodone.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Trazodone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be decreased when it is combined with Trazodone.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Bortezomib.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Trazodone.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Ketorolac.]
[C02KX02, ambrisentan, Trazodone may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Trazodone.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Trazodone.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Trazodone is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Trazodone.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Doxylamine.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Trazodone can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Trazodone may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Trazodone.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Tenoxicam.]
[G04CA03, terazosin, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Trazodone can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terodiline.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Trazodone.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Trazodone.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Trazodone.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Trazodone.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Trazodone.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Trazodone.]
[N06AX14, tianeptine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tianeptine.]
[C09AA02, enalapril, Trazodone may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Trazodone.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Trazodone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Atomoxetine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Toremifene.]
[C03CA04, torsemide, Trazodone may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Trazodone is combined with Tramazoline.]
[C09AA10, trandolapril, Trazodone may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Trazodone.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trazodone.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Trazodone.]
[A03AB08, tridihexethyl, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Trazodone is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Trazodone.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Triptorelin.]
[N04AA12, tropatepine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Trazodone is combined with Troxerutin.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Trazodone.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Trazodone.]
[C02CA06, urapidil, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Trazodone.]
[L01CA04, vinorelbine, The metabolism of Trazodone can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Trazodone.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Epinastine.]
[N06AX16, venlafaxine, Venlafaxine may increase the serotonergic activities of Trazodone.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Trazodone.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Trazodone.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Trazodone is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Trazodone.]
[C09AA15, zofenopril, Trazodone may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zopiclone is combined with Trazodone.]
[N05AX11, zotepine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Trazodone is combined with Anistreplase.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Trazodone is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The serum concentration of Trazodone can be increased when it is combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Trazodone.]
[H05BX01, cinacalcet, The metabolism of Trazodone can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Trazodone.]
[J04AK02, ethambutol, The metabolism of Trazodone can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Trazodone can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Trazodone can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Trazodone.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Trazodone.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibutilide.]
[N04AA05, profenamine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Trazodone.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.]
[L01CB01, etoposide, The serum concentration of Etoposide can be decreased when it is combined with Trazodone.]
[N05AE03, sertindole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Trazodone.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Leuprolide.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Trazodone is combined with Dextran.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Trazodone.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Trazodone is combined with Fibrinolysin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Trazodone.]
[G04BD02, flavoxate, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trazodone.]
[D07AC08, fluocinonide, The metabolism of Trazodone can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Trazodone can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of CNS depression can be increased when Ethanol is combined with Trazodone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Trazodone.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Trazodone can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Trazodone.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Trazodone.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Trazodone.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Trazodone.]
[J05AE10, darunavir, The serum concentration of Trazodone can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Trazodone may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Trazodone is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Trazodone.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Trazodone.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Bifemelane.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cabergoline.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Trazodone.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Trazodone.]
[C05AE01, nitroglycerin, Trazodone may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dofetilide.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trazodone.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Trazodone.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Esmolol.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Trazodone is combined with Fluindione.]
[C09AA09, fosinopril, Trazodone may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Trazodone may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Trazodone.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Trazodone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Trazodone.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Trazodone.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Trazodone is combined with Heparin.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Mesalazine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Trazodone.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Trazodone.]
[J05AG01, nevirapine, The metabolism of Trazodone can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Trazodone is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxatomide.]
[C09AA04, perindopril, Trazodone may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Trazodone may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be decreased when combined with Trazodone.]
[C03AA02, hydroflumethiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Hydroflumethiazide.]
[G04BD06, propiverine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Trazodone.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Trazodone.]
[S01BA13, rimexolone, The serum concentration of Trazodone can be decreased when it is combined with Rimexolone.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Trazodone is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Trazodone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Trazodone.]
[N01AH03, sufentanil, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Trazodone.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Tizanidine.]
[L01CE01, topotecan, The serum concentration of Topotecan can be decreased when it is combined with Trazodone.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Indomethacin.]
[C02CA02, indoramin, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Milnacipran.]
[A03AA30, piperidolate, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Trazodone.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Buclizine.]
[C10AA06, cerivastatin, The metabolism of Trazodone can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Trazodone.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Trazodone is combined with Quinethazone.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Trazodone.]
[N06AA13, iprindole, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Trazodone.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Trazodone.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Trazodone.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Trazodone.]
[C09AA16, imidapril, Trazodone may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Trazodone.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Trazodone.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Trazodone.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Trazodone is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Trazodone.]
[L04AC07, tocilizumab, The metabolism of Trazodone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Trazodone.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Trazodone is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Trazodone is combined with Prasugrel.]
[H02CA04, levoketoconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levoketoconazole.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Trazodone can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mizolastine.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Trazodone.]
[N04BC09, rotigotine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trazodone.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amantadine.]
[C02AA05, deserpidine, Trazodone may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Trazodone.]
[G03AD01, levonorgestrel, The metabolism of Trazodone can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Trazodone can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.]
[C10AA02, lovastatin, The metabolism of Trazodone can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Trazodone can be increased when used in combination with Magnesium sulfate.]
[P03AX03, malathion, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Malathion.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Mazindol.]
[C02BB01, mecamylamine, Trazodone may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Trazodone.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Trazodone.]
[C01AA08, medigoxin, Trazodone may increase the excretion rate of Metildigoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Trazodone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Trazodone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Trazodone is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Trazodone.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Trazodone.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trazodone.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Trazodone.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Trazodone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Trazodone.]
[N06BA03, methamphetamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Metamfetamine.]
[A03AB07, methantheline, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Trazodone.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Trazodone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Trazodone.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Trazodone.]
[H03BB02, methimazole, The serum concentration of Trazodone can be increased when it is combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Trazodone.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Trazodone.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Trazodone.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trazodone.]
[C03AA08, methyclothiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Trazodone.]
[V04CG05, methylene blue, Trazodone may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Trazodone.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Trazodone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Trazodone.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Trazodone.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of hyponatremia can be increased when Trazodone is combined with Metolazone.]
[C07AB02, metoprolol, The metabolism of Trazodone can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Trazodone.]
[N06AX03, mianserin, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Trazodone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Trazodone is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Trazodone.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Trazodone.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Trazodone is combined with Tinzaparin.]
[C09CA03, valsartan, Trazodone may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[D11AX01, minoxidil, Trazodone may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The serum concentration of Trazodone can be decreased when it is combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Trazodone.]
[C01BD01, amiodarone, Amiodarone may increase the QTc-prolonging activities of Trazodone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Trazodone can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Trazodone.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Trazodone.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amodiaquine.]
[G04CA04, silodosin, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[R03BB01, ipratropium bromide, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Trazodone.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Trazodone.]
[N04BC04, ropinirole, Trazodone may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Trazodone.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Nalbuphine.]
[V03AB15, naloxone, The serum concentration of Trazodone can be increased when it is combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Trazodone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Trazodone.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Amphetamine.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Trazodone can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Trazodone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Trazodone.]
[N01AH06, remifentanil, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Trazodone is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Trazodone may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Trazodone can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Trazodone.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nicardipine.]
[C04AE02, nicergoline, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicergoline.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Trazodone is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.]
[N04BC05, pramipexole, Trazodone may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Trazodone may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trazodone.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Trazodone.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Trazodone.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Trazodone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Norfloxacin.]
[C02KX01, bosentan, Trazodone may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Nortriptyline.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Trazodone is combined with Eptifibatide.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Trazodone.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Trazodone is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Trazodone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Trazodone can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Opipramol.]
[N02AA02, opium, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Opium.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Trazodone.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Trazodone is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Trazodone is combined with Ancrod.]
[G04CA02, tamsulosin, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Trazodone can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Trazodone.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trazodone.]
[N02AA11, oxymorphone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Trazodone.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxytocin.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Trazodone is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Trazodone.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Papaverine.]
[N05CC05, paraldehyde, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Trazodone can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Trazodone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pefloxacin.]
[G04BD11, fesoterodine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Trazodone.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pentazocine.]
[N05CA01, pentobarbital, The serum concentration of Trazodone can be decreased when it is combined with Pentobarbital.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Trazodone is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Trazodone.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Trazodone.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Trazodone.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Trazodone.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Trazodone is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pheniramine.]
[N03AA02, phenobarbital, The serum concentration of Trazodone can be decreased when it is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Trazodone is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Phentermine.]
[V03AB36, phentolamine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Trazodone.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Trazodone.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Trazodone.]
[L04AB06, golimumab, The metabolism of Trazodone can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Besifloxacin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Trazodone.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Trazodone.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Trazodone.]
[C09CA02, eprosartan, Trazodone may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pizotifen.]
[J05AG02, delavirdine, The serum concentration of Trazodone can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, Trazodone may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Trazodone.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Trazodone is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Trazodone is combined with Alteplase.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Trazodone.]
[L04AC08, canakinumab, The metabolism of Trazodone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Trazodone is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Trazodone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Trazodone.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Trazodone.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Trazodone.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Trazodone.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Trazodone.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trazodone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Trazodone.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Trazodone can be decreased when it is combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Procainamide.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Trazodone.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Trazodone.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Prochlorperazine.]
[N04AA04, procyclidine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Trazodone can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Trazodone.]
[A03AB05, propantheline, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Trazodone.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Trazodone is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Trazodone is combined with Dalfampridine.]
[S01EB03, ecothiopate, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Echothiophate.]
[A03AB15, diphemanil, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Trazodone.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Trazodone.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Trazodone.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Trazodone.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Trazodone.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Trazodone.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Trazodone can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Trazodone may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Trazodone.]
[J04AB02, rifampin, The serum concentration of Trazodone can be decreased when it is combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Trazodone.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Trazodone.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Trazodone.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Trazodone.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sotalol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Trazodone.]
